Modeling prion-like processing of tau protein in Alzheimer’s disease for pharmaceutical development
Manuscript Number:
17-0727R1
Author(s):
Charles R. Harrington, Björn O. Schelter, John M.D. Storey, Claude M. Wischik, Damon J. Wischik
Disclosures
Charles R. Harrington
Equity:
I have stock options in TauRx Therapeutics
Sponsors:
I am Chief Scientific Officer for TauRx Therapeutics.
Patents/Royalties
I am named inventor on a number of patents relating to compounds and their uses in treatment of Alzheimer's disease and in inhibition of tau aggregation.
Björn O. Schelter
Consulting Fees:
Paid consultant for TauRx Therapeutics.
Grants
Agency:
GTD Dementia research project
Dates:
01.09.2013 - 31.07.2018
John M.D. Storey
Equity:
I have equity stake in the privately listed TauRx Therapeutics
Sponsors:
I serve as Head of Technical at TauRx Therapeutics
Patents/Royalties
I have patents (granted and pending) in the field of synthesis and use of compounds for the treatment of Alzheimer's disease and other related conditions.
Claude M. Wischik
Equity:
I own stock in privately traded TauRx Therapeutics.
Sponsors:
I serve as Executive Chairman for TauRx Therapeutics
Patents/Royalties
I am named inventor on a number of patents relating to compounds and their uses in treatment of Alzheimer's disease and in inhibition of tau aggregation.
Damon J. Wischik
Patents/Royalties
PCT international applications: WO08/155533, WO09/044127, WO09/060191, 2008.